Literature DB >> 8052279

Evolution of therapy for cystic fibrosis.

P B Davis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8052279     DOI： 10.1056/NEJM199409083311011

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Dornase alfa for cystic fibrosis.

Authors:  G Robert; A Stevens; D Colin-Jones
Journal:  BMJ       Date:  1995-09-23

Review 2.  Respiratory medicine.

Authors:  R M du Bois
Journal:  BMJ       Date:  1995-06-17

Review 3.  Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.

Authors:  K L Goa; H Lamb
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

Review 4.  Monitoring early inflammation in CF. Infant pulmonary function testing.

Authors:  Jack K Sharp
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 5.  Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis.

Authors:  H M Bryson; E M Sorkin
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.